SCHEMBL30165296

SCHEMBL30165296

CC(C)(C)OC(=O)N1CCC[C@H](NC(=O)OCc2ccccc2)C1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 4/20 0.63
HSD11B1 P28845 1/20 0.57
CTSL P07711 1/20 0.54
CTSB P07858 1/20 0.54
CTSK P43235 1/20 0.54
DPP4 P27487 3/20 0.53
KCNH2 Q12809 3/20 0.53
DPP7 Q9UHL4 3/20 0.53
EPHX1 P07099 1/20 0.51
ALDH1A1 P00352 1/20 0.50
GAA P10253 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
GABRA5 P31644 1/20 0.49
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 1/20 0.48
PARP1 P09874 1/20 0.48
HPN P05981 1/20 0.47
ST14 Q9Y5Y6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3313427 1.00 USP30 (0.63) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL3313424 1.00 USP30 (0.63) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL13434239 0.97 USP30 (0.59) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL21295099 0.97 USP30 (0.59) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL18391123 0.96 USP30 (0.58) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL21064049 0.96 USP30 (0.58) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL3726979 0.94 HSD11B1 (0.65) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL6944572 0.94 HSD11B1 (0.65) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL951887 0.94 HSD11B1 (0.65) USP30HSD11B1CTSLCTSBCTSK
SCHEMBL29260113 0.93 USP30 (0.56) USP30HSD11B1CTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2024-10-31 US disclosed
EP-4295852-A2 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) Syros Pharmaceuticals, Inc. (US) 2023-12-27 EP disclosed
EP-3484871-B1 PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS INC (US) 2023-06-07 EP disclosed
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) MEDIC LIFE SCIENCES, INC. 2023-03-02 US disclosed
EP-4125895-A1 POTENT AND SELECTIVE IRREVERSIBLE INHIBITORS OF IRAK1 Dana-Farber Cancer Institute, Inc. (US) 2023-02-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360165-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 USP30 1669/4885HSD11B1 1202/4885CTSL 2071/4885
US-20230062491-A1 INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) CDK7, CDK3, CDK9 USP30 1669/4885HSD11B1 1202/4885CTSL 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.